Dir
John W. Childs is an accomplished private equity executive serving as an Independent Director at Biohaven Ltd. (NYSE: BHVN) since September 2022.[[2]](https://www.biohaven.com/about/board-of-directors/)[[5]](https://app.boardroomalpha.com/profiles/people/A1002910-JOHN_W_CHILDS) He is the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm he co-founded in 1995, focusing on life sciences, real estate, and consumer brands.[[2]](https://www.biohaven.com/about/board-of-directors/)[[3]](https://coolidgefoundation.org/the-foundation-historic-site/foundation/john-w-childs/) Previously, he was Senior Managing Director at Thomas H. Lee Company (1991-1995), managing leveraged buyouts, and spent 17 years at Prudential Insurance Company in investment roles.[[2]](https://www.biohaven.com/about/board-of-directors/)
Childs has a distinguished board career, including past Chairmanships at CHG Healthcare Services, Sunny Delight, and Kosta Browne, and current directorships at Realm, LLC (premium Napa wines), Pyramid Biosciences, OMAX Health, and Basin Holdings.[[2]](https://www.biohaven.com/about/board-of-directors/)[[3]](https://coolidgefoundation.org/the-foundation-historic-site/foundation/john-w-childs/) On November 13, 2025, he purchased 3,333,333 common shares of Biohaven for $25 million at $7.50 per share, increasing his holdings by 52%, signaling strong confidence in the company.[[1]](https://www.investing.com/news/insider-trading-news/biohaven-ltd-director-childs-buys-25m-in-common-shares-93CH-4362079)[[4]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/independent-director-of-biohaven-john-childs-buys-52-more-sh) He holds a B.A. from Yale University and an M.B.A. from Columbia University.[[2]](https://www.biohaven.com/about/board-of-directors/)[[3]](https://coolidgefoundation.org/the-foundation-historic-site/foundation/john-w-childs/)
View full insider profile →
